This inventor holds 1 USPTO granted patent. Top assignee: B.m.r.a. Corporation B.v.. Active years: 2000.
Company Filing History:
Years Active: 2000
Title: Inventor Spotlight: Manfred Mutter and his Innovative Template Associated NPY Y2-Receptor Agonists
Introduction:
In the world of inventions and patents, Manfred Mutter, hailing from Vaud, Switzerland, stands out as a brilliant mind. With a keen interest in neuropeptide Y (NPY) and its potential therapeutic applications, Mutter has made significant contributions to the field through his groundbreaking invention of Template Associated NPY Y2-Receptor Agonists. Let's delve deeper into his achievements and journey.
Latest Patents:
Manfred Mutter has successfully secured one patent for his remarkable invention, the Template Associated NPY Y2-Receptor Agonists. This invention harnesses the power of neuropeptides, specifically NPY or PYY, by combining them with a template that promotes biologically active folds. The use of cyclized peptides with naphthyl ring structures within the templates allows for enhanced therapeutic potential. These agonists have shown promise in the treatment of various diseases and conditions, including asthma, rhinitis, and bronchitis.
Career Highlights:
Mutter's career has been defined by his relentless pursuit of scientific advancements. Currently affiliated with B.m.r.a. Corporation B.v., Mutter's dedication and expertise have played a pivotal role in taking this company to new heights. His in-depth understanding of neuropeptide Y and its therapeutic potential has contributed significantly to the success of the company's research and development efforts.
Collaborations:
Collaboration often fuels innovation, and Manfred Mutter is no stranger to fruitful partnerships. Alongside his solo endeavors, Mutter has worked closely with esteemed colleagues Jean-Silvain Lacroix and Eric Grouzmann. Their collective expertise in peptide research and their shared passion for medical advancements have resulted in numerous successful collaborations over the years. Mutter's ability to form effective collaborations demonstrates his commitment to driving scientific progress.
Conclusion:
Manfred Mutter's invention of Template Associated NPY Y2-Receptor Agonists has undoubtedly left a lasting impact on the field of medical research. Through his groundbreaking work, patients suffering from diseases and conditions responsive to NPY or PYY may find new hope in more effective treatments. Mutter's career highlights and strong collaborations stand as a testament to his exceptional dedication to advancing scientific knowledge and improving healthcare outcomes. Continued support and recognition of inventors like Manfred Mutter are essential for fostering a culture of innovation and finding novel solutions to pressing medical challenges.